- Home
- MYN vs PHAT Comparison
MYN vs PHAT Comparison
Compare MYN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- PHAT
- Stock Information
- Founded
- MYN 1992
- PHAT 2018
- Country
- MYN United States
- PHAT United States
- Employees
- MYN N/A
- PHAT N/A
- Industry
- MYN Finance Companies
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- PHAT Health Care
- Exchange
- MYN Nasdaq
- PHAT Nasdaq
- Market Cap
- MYN 382.4M
- PHAT 339.8M
- IPO Year
- MYN N/A
- PHAT 2019
- Fundamental
- Price
- MYN $9.49
- PHAT $3.96
- Analyst Decision
- MYN
- PHAT Strong Buy
- Analyst Count
- MYN 0
- PHAT 5
- Target Price
- MYN N/A
- PHAT $22.50
- AVG Volume (30 Days)
- MYN 86.0K
- PHAT 1.2M
- Earning Date
- MYN 01-01-0001
- PHAT 05-08-2025
- Dividend Yield
- MYN 4.12%
- PHAT N/A
- EPS Growth
- MYN N/A
- PHAT N/A
- EPS
- MYN N/A
- PHAT N/A
- Revenue
- MYN N/A
- PHAT $55,252,000.00
- Revenue This Year
- MYN N/A
- PHAT $202.23
- Revenue Next Year
- MYN N/A
- PHAT $113.81
- P/E Ratio
- MYN N/A
- PHAT N/A
- Revenue Growth
- MYN N/A
- PHAT 8001.47
- 52 Week Low
- MYN $8.47
- PHAT $3.81
- 52 Week High
- MYN $10.62
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- MYN 39.21
- PHAT 37.83
- Support Level
- MYN $9.43
- PHAT $3.87
- Resistance Level
- MYN $9.61
- PHAT $5.09
- Average True Range (ATR)
- MYN 0.18
- PHAT 0.59
- MACD
- MYN -0.01
- PHAT -0.10
- Stochastic Oscillator
- MYN 32.18
- PHAT 6.12
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.